Creative Planning
NRSN icon

Creative Planning’s NeuroSense Therapeutics NRSN Stock Holding History

Creative Planning’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.99K Hold
11,911
– – ﹤0.01% 4077
2025
Q4 		$9.16K Buy
+11,911
New +$12.5K ﹤0.01% 3872

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's NRSN Position: Q1 2026 in Review

Creative Planning held its NeuroSense Therapeutics (NRSN) position steady in Q1 2026 at 11,911 shares worth $8.99K. The position accounts for ﹤0.01% of the portfolio, ranked #4077.

Creative Planning first reported a position in NRSN in Q4 2025 and has held it in 2 quarters since. The position peaked at $9.16K in Q4 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • Creative Planning held 11,911 shares of NeuroSense Therapeutics worth $8.99K as of Q1 2026.
  • Creative Planning left its NeuroSense Therapeutics share count unchanged in Q1 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #4077 holding.
  • Creative Planning first reported a position in NeuroSense Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Creative Planning's NeuroSense Therapeutics position peaked at $9.16K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.